Efficacy of MK615 for the treatment of patients with liver disorders

doi:10.3748/wjg.v18.i31.4118

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 31

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4649)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

470

HTML

3918

Figures (1-4)

142

Tables (1-3)

119

Sum=4649

Aug 21, 2012 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastroenterol. Aug 21, 2012; 18(31): 4118-4126
Published online Aug 21, 2012. doi: 10.3748/wjg.v18.i31.4118

Full Size Figure Download Figure

Figure 3 Effects of MK615 in patients with liver disorder, chronic hepatitis C and non-alcoholic fatty liver disease. A: Alanine aminotransferase (ALT); B: Aspartate aminotransferase (AST); C: Chronic hepatitis C group (ALT); D: Non-alcoholic fatty liver disease group (ALT). ^aP < 0.05 vs 0 wk group. Dunnett’s test.

Citation: Hokari A, Ishikawa T, Tajiri H, Matsuda T, Ishii O, Matsumoto N, Okuse C, Takahashi H, Kurihara T, Kawahara KI, Maruyama I, Zeniya M. Efficacy of MK615 for the treatment of patients with liver disorders. World J Gastroenterol 2012; 18(31): 4118-4126
URL: https://www.wjgnet.com/1007-9327/full/v18/i31/4118.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i31.4118